Dr Kosiborod is an internationally recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, and quality care and outcomes.
Published: 13 July 2020
In this series, Mikhail Kosiborod and Hertzel Gerstein discuss the effects of Covid-19 and metabolic disease, early treatment with metabolic therapies and the Phase III DARE-19 Trial looking at dapagliflozin in Covid-19 patients.
Recorded remotely from Hamilton and Kansas City, 2020.
The Effect of COVID and Metabolic Disease and Early TreatmentWatch now
Metabolic Therapy TreatmentsWatch now
Phase III DARE-19 TrialWatch now